MIRMMirum Pharmaceuticals Inc
MIRM
Mirum Pharmaceuticals Inc1,633
Mkt Cap
$5.91BVolume
471,750.0052W High
$109.2852W Low
$38.22PE Ratio
-204.87MIRM Fundamentals
Price
$97.95Prev Close
$95.86Open
$96.3450D MA
$95.37Beta
0.79Avg. Volume
1.03MEPS (Annual)
-$0.4654P/B
16.15Rev/Employee
$1.4M$3,901.29
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
Zacks·2d ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards...
Business Wire·6d ago
Tudor Investment Corp ET AL Takes $2.03 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
Tudor Investment Corp ET AL bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·7d ago
18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC
SG Americas Securities LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·13d ago
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rat...
MarketBeat·16d ago
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·18d ago
JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM
JPMorgan Chase & Co. lessened its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 79.1% during the third quarter, according to the company in its most recent Form 13F...
MarketBeat·20d ago
Hennion & Walsh Asset Management Inc. Sells 17,560 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Hennion & Walsh Asset Management Inc. reduced its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,294 shares of the com...
MarketBeat·21d ago
Tudor Investment Corp ET AL Makes New $2.03 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM
Tudor Investment Corp ET AL acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 27,654 shares of the compa...
MarketBeat·22d ago
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $125.00
TD Cowen upped their price objective on shares of Mirum Pharmaceuticals from $117.00 to $125.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·23d ago
<
1
2
...
>